Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 94 USD -3.01% Market Closed
Market Cap: 6.5B USD
Have any thoughts about
Lantheus Holdings Inc?
Write Note

Lantheus Holdings Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lantheus Holdings Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Lantheus Holdings Inc
NASDAQ:LNTH
Current Portion of Long-Term Debt
$564.7m
CAGR 3-Years
279%
CAGR 5-Years
123%
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Current Portion of Long-Term Debt
$5.4m
CAGR 3-Years
-60%
CAGR 5-Years
-37%
CAGR 10-Years
12%
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Current Portion of Long-Term Debt
$422m
CAGR 3-Years
41%
CAGR 5-Years
104%
CAGR 10-Years
14%
ICU Medical Inc
NASDAQ:ICUI
Current Portion of Long-Term Debt
$52m
CAGR 3-Years
343%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lantheus Holdings Inc
Glance View

Economic Moat
Wide
Market Cap
6.5B USD
Industry
Health Care

Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.

LNTH Intrinsic Value
127.81 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Lantheus Holdings Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
564.7m USD

Based on the financial report for Sep 30, 2024, Lantheus Holdings Inc's Current Portion of Long-Term Debt amounts to 564.7m USD.

What is Lantheus Holdings Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
123%

Over the last year, the Current Portion of Long-Term Debt growth was 80 573%. The average annual Current Portion of Long-Term Debt growth rates for Lantheus Holdings Inc have been 279% over the past three years , 123% over the past five years .

Back to Top